New Product Planning
Maximize Asset Value Through Strategic New Product Planning
Turning Innovation into Impact Across the Healthcare Ecosystem
The Dedham Group partners with pharma companies on new product planning (NPP) to maximize asset value to drive better patient outcomes, meet market needs, and align with healthcare system priorities. We integrate scientific innovation, market insights, and strategic planning at every stage of development.
Schedule a Meeting
Our Tailored Services for Success
Target Product Profiling and Brand Strategy
Understand the product drivers and parameters that will ensure assets have differentiation in the market and provide incremental value for stakeholders over the standard of care.
Pressure test product profile metrics with key opinion leaders and payers to determine the impact of each of the variables and what is needed in a trial design to ensure commercial success.
Develop a brand strategy and marketing plan through understanding of the key product differentiators and how it could be positioned in both the current landscape and future landscape to maximize success.
RWE and Competitive Analysis
Leverage real world data and the current and future competitive landscape to help inform product development, positioning, and go-to-market strategy.
Analyze current treatment patterns, patient and physician distribution, and treatment geographies and sites of care to understand key trends and behaviors in the market.
Inform the commercialization strategy through analysis of competitor pricing, promotional tactics, and clinical advancements as well as understanding of the competitive pipeline.
We Provide:
Unparalleled Commercial Expertise
Commercial capabilities extend seamlessly across an organization’s growth stages and the entire lifecycle of an asset.
Data-Driven Excellence
Harness the power of cutting-edge analytics and extensive research for informed, strategic decisions.
Industry Mastery
Additional Resources:
State Drug Importation Programs: Key Considerations for Manufacturers
In the government’s ongoing pursuit of lower drug prices for American patients, the FDA’s Drug Importation Program, approved in Florida in January, allows states to import prescription drugs from Canada, where prices can be meaningfully lower.
